The High Throughput Screening (HTS) Core assists City of Hope researchers in the identification of novel lead compounds for the development of anticancer drugs and of chemical probes useful for biochemical mechanistic studies. These objectives are achieved via sophisticated, high throughput screening assays of synthetic compound and natural product libraries.
A team of medicinal chemists, pharmacologists, structural biologists, bioinformaticians, and clinicians contributes valuable input and expertly optimizes some of these small molecules for the development of life-saving, cancer-fighting drugs. The team then translates these molecules and drugs into clinical evaluation in cancer patients.
With a library of over 75,000 synthetic compounds that represent prime leads for drug development, as well as a library of over 7,000 natural product extracts comprising nearly 1 million individual compounds, the HTS Core serves as a remarkable resource for the better understanding and advancement of powerful cancer treatments and strategies.
Summary and Advantages
The HTS Core is a full-time, professionally managed facility, boasting highly trained and experienced staff, advanced equipment, and a substantial library of compounds. These attributes, combined with a centralized knowledge base, increase cost-effectiveness and productivity in the ongoing battle against cancer.
Investigators also benefit from the cumulative experience gleaned from other projects in the High Throughput Screening Core.
Research reported in this publication included work performed in the High Throughput Screening (HTS) Core and supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
This core is a Cancer Center Support Grant (CCSG) Sponsored Core.